Please use this identifier to cite or link to this item: https://doi.org/10.1007/s10529-010-0423-5
DC FieldValue
dc.titleTherapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers
dc.contributor.authorXie, Z.
dc.contributor.authorChng, W.J.
dc.contributor.authorTay, K.G.
dc.contributor.authorLiu, S.C.
dc.contributor.authorZhou, J.
dc.contributor.authorChen, C.-S.
dc.date.accessioned2014-12-12T08:02:45Z
dc.date.available2014-12-12T08:02:45Z
dc.date.issued2011-02
dc.identifier.citationXie, Z., Chng, W.J., Tay, K.G., Liu, S.C., Zhou, J., Chen, C.-S. (2011-02). Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers. Biotechnology Letters 33 (2) : 221-228. ScholarBank@NUS Repository. https://doi.org/10.1007/s10529-010-0423-5
dc.identifier.issn01415492
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/117200
dc.description.abstractPurpose of work: Mutation of the p53 gene is the most common genetic alteration in human cancers. Our study proposes to rationally design a p53 antisense oligonucleotide (ASO) repository, which contains a series of ASOs containing single nucleotide differences to discriminate between each mutant and wild type (WT) p53. The Sfold software was used to predict target-accessibility and we designed an initial series of antisense oligonucleotides (ASO) that target the p53 mutants A161T, R175H and R249S. Western-blot analysis indicated that ASOs strongly inhibited the expression of p53 mutants in a panel of human tumor cell lines (SNU-449, SK-BR-3 and PLC/PRF/5) while having little effect on the expression of WT p53 (HepG2 cells). In three cancer lines harboring each of the p53 mutations, mutant-specific ASO treatment led to a dose-dependent inhibition of cell growth, cell viability, colony formation and invasion, and expression of mutant p53-dependent survival proteins. Our preliminary results indicate that a single nucleotide difference in ASOs can discriminate between mutant and WT p53. These observations support the hypothesis that a p53 ASO repository can be a potentially valuable tool to knock down oncogenic mutant p53 and warrant the testing of a p53 ASO repository in in vivo settings. © 2010 Springer Science+Business Media B.V.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1007/s10529-010-0423-5
dc.sourceScopus
dc.subjectAntisense oligodeoxynucleotide
dc.subjectCarcinoma
dc.subjectMutation
dc.subjectp53
dc.typeArticle
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.description.doi10.1007/s10529-010-0423-5
dc.description.sourcetitleBiotechnology Letters
dc.description.volume33
dc.description.issue2
dc.description.page221-228
dc.description.codenBILED
dc.identifier.isiut000286198700003
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.